This bill matters because it addresses a long-standing issue in medical research: the lack of diversity in clinical trials. When new drugs and medical devices are primarily tested on one demographic group, it can be unclear how safe or effective they will be for other populations. Different groups can respond differently to treatments due to genetic, environmental, or lifestyle factors.
If this bill becomes law, it could lead to better, more equitable healthcare by ensuring that treatments are tested on a broader range of people, leading to more tailored and effective medicines for everyone. It directly tackles financial barriers that often prevent people, especially those from lower-income or rural communities, from participating in trials. If it doesn't pass, these barriers will likely remain, and clinical trials may continue to lack the diverse representation needed to develop truly universal healthcare solutions, potentially leaving some populations with less effective or even unsafe treatments.
KEY PROVISIONS
4AI-extracted
PROVISION 01
Establishes a grant program to support community education, outreach, and recruitment for clinical trials, specifically targeting underrepresented populations.
This provision directly funds efforts to reach and inform communities that have historically been excluded from or have faced barriers to clinical trial participation.
PROVISION 02
Clarifies that payments to clinical trial participants for expenses like travel, transportation, and meals are not illegal inducements under federal law.
This removes a significant financial barrier for participants and legal risk for trial sponsors, encouraging broader participation, especially from those with limited financial resources.
PROVISION 03
Ensures that providing digital health technologies (e.g., apps, devices) free of charge to participants is not considered an illegal inducement if it facilitates participation by underrepresented populations and is necessary for the trial.
This allows trials to leverage modern technology to improve accessibility and engagement for diverse participants without legal concerns.
PROVISION 04
Specifies that drug and device manufacturers can pay for a participant's cost-sharing obligations (e.g., deductibles, co-pays) for clinical trial-related care without violating anti-kickback or false claims laws, provided certain conditions are met.
This directly tackles another major financial barrier, making it feasible for more individuals to join trials without incurring significant out-of-pocket medical expenses.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill matters because it addresses a long-standing issue in medical research: the lack of diversity in clinical trials. When new drugs and medical devices are primarily tested on one demographic group, it can be unclear how safe or effective they will be for other populations. Different groups can respond differently to treatments due to genetic, environmental, or lifestyle factors.
If this bill becomes law, it could lead to better, more equitable healthcare by ensuring that treatments are tested on a broader range of people, leading to more tailored and effective medicines for everyone. It directly tackles financial barriers that often prevent people, especially those from lower-income or rural communities, from participating in trials. If it doesn't pass, these barriers will likely remain, and clinical trials may continue to lack the diverse representation needed to develop truly universal healthcare solutions, potentially leaving some populations with less effective or even unsafe treatments.
KEY PROVISIONS
AI-extracted
high
Establishes a grant program to support community education, outreach, and recruitment for clinical trials, specifically targeting underrepresented populations.
This provision directly funds efforts to reach and inform communities that have historically been excluded from or have faced barriers to clinical trial participation.
high
Clarifies that payments to clinical trial participants for expenses like travel, transportation, and meals are not illegal inducements under federal law.
This removes a significant financial barrier for participants and legal risk for trial sponsors, encouraging broader participation, especially from those with limited financial resources.
med
Ensures that providing digital health technologies (e.g., apps, devices) free of charge to participants is not considered an illegal inducement if it facilitates participation by underrepresented populations and is necessary for the trial.
This allows trials to leverage modern technology to improve accessibility and engagement for diverse participants without legal concerns.
high
Specifies that drug and device manufacturers can pay for a participant's cost-sharing obligations (e.g., deductibles, co-pays) for clinical trial-related care without violating anti-kickback or false claims laws, provided certain conditions are met.
This directly tackles another major financial barrier, making it feasible for more individuals to join trials without incurring significant out-of-pocket medical expenses.
Grants to encourage clinical trial enrollment by underrepresented populations
discretionary
Fiscal Years 2025 and 2026
GLOSSARY
AI-written
Clinical trial
Research studies conducted with human volunteers to evaluate new medical treatments, drugs, or devices to see if they are safe and effective.
Underrepresented population
Groups of people, as defined by the National Institutes of Health and Food and Drug Administration, who historically have not been adequately included in clinical trials, often including racial and ethnic minorities, rural communities, and other specific demographics.
Grants
Money provided by the government to organizations for specific projects or purposes, which does not need to be paid back.
Social Security Act (Civil Monetary Penalties Law)
A federal law that allows the government to impose financial penalties for certain fraudulent or abusive practices related to federal healthcare programs.
Anti-Kickback Statute
A federal law that prohibits knowingly and willfully offering, paying, soliciting, or receiving any remuneration (anything of value) to induce or reward referrals for items or services payable by federal healthcare programs.
False Claims Act
A federal law that makes it illegal to knowingly submit false or fraudulent claims for payment to the government, often used in cases of healthcare fraud.
ACTION TIMELINE
2 EVENTS
MAY 20, 25
Introduced in House
INTROREFERRAL
MAY 20, 25
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The portion of medical expenses that an insured person must pay out of their own pocket, such as deductibles, co-payments, or co-insurance.
Digital health technologies
Tools and devices, often electronic, used to improve health and healthcare delivery, such as mobile health apps, wearable sensors, or telehealth platforms.
